- A general idea about the size of acquisitions
- Matt Vincent's slide deck is up from today's presentation!
- Lonza Group - My Email Exchange and Open Questions
- Moi tweet
- Is $100 Billion Reasonable?
- 20/40 story picked up at KurzweilAI
- Positive thoughts for Patti ( pm1469 )
- Marketwatch/Wall Street Journal Article on 20/400 to 20/40
- Experimental Stem Cell Treatment Restores Blind Man's Sight So Well, He Can Drive
- Malpractice risk and compassionate use--the ugly truth
- ACTC Video/Audio Archive
- Links...there's strength in numbers!
- Ceasar de Cuenca is Carrying the Water for ACT.....great post on main forum
- UPI has it too!
- MSN Carries "Blind man" Story
- The Importance of a Trial (or lack thereof)
- ACTC vs Mesoblast - A JV example comparison
- Scimitar Equity Blog on ACTC
- New Scientist Article About 20/40 Patient Improvememt Is A Man
- Let's inject the 20/100 patients now.
- Patient in ACTC Stem Cell Clinical Trial With Dry AMD Goes from Legally Blind (20/400) to Near Normal Vision (20/40)
- ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40
- What is your expectation for share price in...
- Do you have a Plan in Place now for the ride to Millioniare Status?
- The Mechanics of the Trials
- This months edition of AARP " Are Your Eyes Healthy"
- NOW we have 3000, or rather 3002 members
- A Note to the Media
- The next day... How is 20/40 looking to the investors here today?
- Is it me, or does it seem the IIa trials are proceeding slowly?
- Foundation for Fighting Blindness, finally a little coverage
- Buyout.
- Google spreadsheet
- ACTC - ACT Confirms Clinical Trial Participant Showed Improvement in Vision from 20/400 to 20/40 Following Treatment
- ACT Really Is Off The Radar.........
- SA- A Breakdown Of Advanced Cell Technology's Latest Conference Call
- Ladies and Gentleman.... The Big Michael!!!
- Robert Lanza at TEDTalk (How did I miss this!)
- Cloning Technique Produces Human Stem Cells For The First Time
- One patient's vision went from 20/400 to 20/40, said Lanza.
- CFO and SEC Settlement
- Question about BOD compensation package.
- Cambridge area tops list of iPS cell patent-holders
- Will they get it done?
- CFO Position???
- Gmp
- 3 Scenarios
- Platelets Question: Is this a problem?
- Who asked Lanza about animal stem cell products?
- Advanced Cell Technology Reports Net Loss, Plans CFO Hire
- IMO Most Important Statement by Rabin During the CC
- Gary's Transcript ACT CC presentation 5/9/13
- Rating this CC to others. Pass/Fail
- Transcript for Conference Call, 5/09/13
- Am I being overly optimistic?
- Are you happy with your ACTC investment at this moment?
- Actc - 10q
- CC Comments
- Position of Strength
- Is anyone else disappointed ACT did not have major/minor press release before today's CC?
- Haven't seen this article anywhere
- Patients In in 150k cohort and patient on 2a cohort
- Rehabilitating Gary Rabin; do we need to restructure the ACTC command center?
- Pharma Television May 15, 2013 Gary Rabin interview
- Another Opportunity to Voice to NIH?
- The Latest Developments in Stem Cell Therapy for Macular Disease
- Robert Langer wins Pre Nobel.
- What are the Chances?
- I sometimes worry about getting the undereducated public to understand our science..
- Robert Langer Receives the “pre-Nobel Prize”
- Matt Vincent To Speak At 8th Annual World Stem Cells Congress on May 22 in UK
- 2013: Year of the Stem Cell
- Questions for the CC
- The Little Cell That Could
- Pluripotent Stem Cells - ACTC's Broad Scientific Positioning
- ACTC - Advanced Cell Technology to Host Conference Call to Discuss 2013 First Quarter Results and Provide a Corporate Update on Thursday, May 9th
- Number of AMD studies - AMD increasing to nearly 300 million in 2040
- AARP talks about Eye openers May 2013
- Patients First Act of 2013
- Article regarding CIRM
- Diabetic Retinopathy
- Mathew Vincent - Presentation at Stem Cells USA Sept. 2012
- Nih:
- FFB Seminar 1/6/2013 Conversation with Dr. Dean Eliott YouTube Link
- 20/100 SMD Patient
- GE - Progressing Biotechs
- third cohort patients
- Big Cat, Michael.... THE KING!! New article!!
- Anyone think Biotime's former CFO is coming to ACT??
- Cohort 2a Question
- The Embryo Project Encyclopedia
- FFB Seminar Dr. Dean Eliott Audio Link to Youtube
- RPE Surgical Procedure
- SEC settlement not the only thing holding us down?
- My Preliminary ACT Valuation
- Are we getting enough love from the results of the clinical trials so far?
- ACTC's most recent tweet. Less than an hour ago. 4-24-13
- A New Competitor in the SMD and Dry AMD Pools
- Biogen Idec
- ACT Initiates Higher-Dosage Patient Treatment in European Clinical Trial for Macular Degeneration
- Merger and Aquisition
- another week with no injections.
- The moral dilemma
- Vertex has a big day, Is our turn coming?
- IRB and UK Amendment
- Regenmed 4/17 slides up
- Right now my number 1 concern is to treat more patients with 20/100 vision
- Reg Med Meeting
- Should GR Resign?
- Talked to someone at Bascom Palmer
- 4/17/13 Regen Med Investor Day
- Official ACT PR for Regen Med Investor Day
- ACT Treats First Patient with Better Vision in Clinical Trial for Stargardt’s Macular Dystrophy
- Not Since January of 2009
- Advanced Cell Technology, Cytomedix and Mesoblast to Provide Corporate and Clinical Updates at Regen Med Investor Day
- Wouldnt it be groundbreaking if a forum like ours could elect a board member
- CEOcast Sunday, April 07 2013
- Non-Embryonic Stem Cells: The Dawning of a New Era of Hope
- Dr. Lanza's latest tweet. 4/4/13
- 20/100
- The RPE "competition"
- 20/20 or 20 out of 20 a small quiz
- Seeking Alpha - Phase II Trials Will Be Pivotal For These Stem Cell Companies
- BioResearch OpenAccess--editorial board in formation
- 150k cells, congratulations to all iCell follower!
- ACT Initiates Treatment of Higher-Dosage Cohort in Clinical Trials for Dry Age-Related Macular Degeneration and Stargardt?s Macular Dystrophy
- Peizer double dipping? ACT shipped syringe and his recent deal with Unilife
- 20/100 patients : are we going to inject into the fovea ?
- From past ACT press releases, two federally funded grants
- Revenue Opportunity for RPE Cells at Injection Capacity Limit – Rough Estimates.
- Support for hesc research is now beyond my wildest expectations
- Taking stock of my investment and the power of Investorstemcell
- Robert Lanza on Exploration KPFA 94.1 3/26/13 (archived)
- ACTC - New CORPORATE FACT SHEET UPDATE
- Dr Gary Rabin, CEO, ACT to present at Ministry of Sciences’ London Stem Cell Evening event
- So Who's MS Ass Might be Hanging Out?
- Question on derivation technique and its patent
- Video of Dr. Lanza giving Keynote in Hilton Head, 3/24/13
- Mass Eye and Ear holding more Meetings in Florida Today?Tomorrow
- FFB Houston chapter Save Sight Saturday
- Seeking Alpha - The Future Of Medicine: A Look At 5 Stem Cell Companies
- Bausch & Lomb raising cash in IPO - up to $1.5B
- Vail Vitrectomy - A Thought
- ACTC - ACT’s Chief Scientific Officer Dr. Robert Lanza to Deliver the Nerem Lecture 2013 at the 17th Annual Hilton Head Workshop
- June 1, 2013
- Video: Gary Rabin on Panel in Barcelona
- AstraZeneca Paying Record $240M Upfront in mRNA Deal With Moderna
- World Stem Cells- Regenerative Medicine Congress 2013
- Download Presentation: Advanced Cell Technology’s Clinical Trial Progress
- NIH Approved 7 New Stem Cell Lines on 03/18/2013
- Phase II Trials Will Be Pivotal For These Stem Cell Companies
- Phase II Trials Will Be Pivotal For These Stem Cell Companies - Seeking Alpha, someone other that our own BigCat!
- Lanza's Employment agreement ends 9/30/13..
- ACT Mention In Article About Dr. Atala
- Bio-Europe Spring 2013 - Barcelona Report by msemporda - Forum Q&A Link
- iCell Travelers reporting from the field....
- ACTC and CHA Biotech
- Patient Inclusion/Exclusion Criteria
- The Langer Lab, NASA, Synthecon, and the ACT bioreactor
- Cohort 2A is safety an issue
- Data continues to build from Bio-Europe - incl. Videos, meeting details with GR & MV plus Q&A
- Beware of the "Ides of March"
- Great NPR interview w/Dr. Langer just posted!
- What are the chances of a country approving the use of our cells for stem cell tourism?
- The dawn of de-extinction. Are you ready?
- Advanced Cell Technology Receives Approval from Data Safety Monitoring Board (DSMB) to Initiate Treatment of Third Patient Cohort in All Three Clinical Trials
- SEEKING ALPHA - 2 Biotech Stocks with Huge Potential For The Speculative Investor
- dr langer is involved!!
- After injecting 18 patients THIS is what is STILL BEING REPORTED (Frustrating)
- Dr. Coffey's long AMD interview on Australian Broadcast March 11 2013
- Stem Cell Commercialization and Partnering, April 29-30, 2013, Boston, MA
- Why the obsession with iPS cells?
- presentation from barcelona
- Bio Europe Slides - 3/12/2013
- ACTC - Official press release for Lanza...
- Lanza Quoted In Cloning Article
- Could this be ACTC Government Grant Opportunity for Platelets?
- Lanza named to top 50 global stem cell influencers
- U.S. Climate Warms for Stem Cell Research
- BIO CEO & Investor Conference, New York City, February 11, 2013 (PDF)
- Good Article in the Huff and Puff Post
- Tweet from Barcelona
- Random tidbits from surfing the web today
- Fix Me Documentary - [BBC Horizon]
- Timeline of NIH Redefinition and Lack Thereof
- article on stem cells and amd, trial mention
- Conference Call Article
- Vail Vitrectomy: Controversial Elitism or Educational Masterpiece
- Everything this year hinges on 20/100 results
- PR: March 8
- DOD grant related to blood - Dept of Army
- Conference Call 3/07/13 Transcript
- ACTC - 10k
- ACTC - 4th Quarter and Year Results
- Repair of the degenerate retina by photoreceptor transplantation
- this seems like an old article, what do you guys think?
- Conference Call 3/7/2013
- New potential Adult Pluripotent stem cell type found - "ePS"
- Fact Sheet Updated:
- National Heart, Lung, & Blood Symposium on Cardiovascular Regenerative Medicine, Sept 25th
- ACT - Predictions for the rest of 2013
- Pfizer's Cash Position Is Signaling Activity - SA article
- Novartis CEO Joseph Jimenez outlines a new paradigm for blockbuster medications.
- Stem cells: a new paradigm for disease modeling and developing therapies for age-related macular degeneration
- ACTC clinical partner UCLA received approval of its IND
- Artificial blood from stem cells
- Has Dr. Robert Langer being on the Board helped?
- UCLA receives approval to initiate Phase I/II myopia study
- Nature News Article - iPS, Lanza, Platelets
- Seeking Alpha Article on FDA Accelerated Approval Changes
- Let's keep our eye on the ball....
- ACT Programs & Collaborators
- Could this be part of GR strategy?
- I just want to be productive. I just want to be appreciated for what I do.
- Pivotal Trials, Accelerated Approval & Controls
- GE & Samsung Wake Up!
- 1st RegenMed INVESTOR Conf - April 17th, NYC
- Ned 7......?
- Facebook, Google Founders Sponsor $33 Million Breakthrough Prize To Reward Life Science Research, Announce Inaugural Winners
- DSMB approval??
- Breakthrough prize in life sciences
- Interview with Steven Levy, President of MD Stem Cells(anecdotal results in eyes)
- Potential JV order
- FDA approves UCLA IND application to commence embryonic stem cell-based trial
- Decison already made?
- Genentech Tweets about AMD
- ACT Now Owns a Magazine ??????
- International Stem Cell Corp. Strengthens Intellectual Property Portafolio
- Critical mass
- What rate do you think insurance companies will agree to pay for ACTC's RPE treatment (per eye)?
- Who (or how many) are selling keeping pps down here on iCell?
- The Case for Platelets-ACT on route to engineer new roles
- Any comments on changes to ISCO license?
- The Race Is On...
- ACT Uplist and Reverse Split
- ACTC - Maurie Hill next update....
- What will the Reverse Ratio Be?
- Thursday at 4:50ET President Obama will be hosting a Hangout on Google+.
- Will A Rising Tide Lift All Boats??
- What are the principles of successful investment?
- Wikipedia - Macular Degeneration (ACT trials mentioned)
- ACTC on Seeking Alpha
- Dr. Robert Lanza named Editor-in-chief of BioResearch Open Access, a Quality Peer-Reviewed Journal from Mary Ann Liebert, Inc. (publishers that provide a forum for a broad spectrum of Scientific Topics)
- (PDF) ACTC - BIO CEO & Investor Conference, New York, NY
- Do We Know The Actual Methods To Be Used??
- 2 Stem Cell Research Pioneers And Where They Are Today - Seeking Alpha 2/11/13
- ACT's Clinical Partner Receives FDA Approval to Initiate Clinical Trial Using the Company's hESC-derived Cells to Treat Severe Myopia
- Look
- Cornea IND
- Ten companies with innovative stem cell therapies in clinical trials.